Systemic co‐delivery of sorafenib and siCFL1 by reduction‐responsive NPs could effectively silence CFL1 expression and enhance sorafenib sensitivity in vivo, thereby leading to a significant inhibition of HCC tumor growth. The gene discussed is CFL1; the disease is neoplasm.